Rubicon® RESEARCH

INNOVATION | QUALITY | CARE

Date: July 20, 2026

To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street – Fort
Mumbai 400 001
Scrip Code: 544578

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
NSE Symbol: RUBICON

Sub: Outcome of Board Meeting - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Madam/Sir,

Pursuant to Regulation 30 and 42 of the SEBI Listing Regulations, we hereby notify that the Board of Directors of the Company at its meeting held today i.e., July 20, 2026, has inter-alia considered and approved:

1. **Date of 27th Annual General Meeting and Record Date for payment of final dividend on equity shares for the financial year 2025-26.**

(a) 27th AGM of the Company to be held on Wednesday, August 26, 2026, through Video Conferencing / Other Audio Visual Means; and

(b) Fixed the 'Record date' as follows:

Symbol	Type of Security	Record Date	Purpose
BSE: 544578 NSE: RUBICON	Fully paid-up equity shares of face value Re. 1/- each (ISIN: INE506V01022)	Friday, August 7, 2026.	Determination of members eligible for payment of final dividend for the financial year 2025-26, on fully paid-up equity shares.

The Board of Directors, at its meeting on May 29, 2026, recommended a final dividend of ₹1.50 per equity share (face value ₹1/- each fully paid-up) for the financial year ended March 31, 2026. Subject to members approval and deduction of tax at source, the dividend will be paid within 30 days from the date of approval. The payment will be made to those members and beneficial owners whose names are recorded in the Register of Members or depository records as of the close of business hours on Friday, August 7, 2026.

Rubicon® RESEARCH

INNOVATION | QUALITY | CARE

2. **Update on the merger of Kia Health Tech Private Limited, Wholly Owned Subsidiary, with Rubicon Research Limited:**

   Further to the in-principle approval granted on February 3, 2026, the Board of Directors of both respective companies have placed and approved the Scheme of Merger for Kia Health Tech Private Limited, a wholly owned subsidiary, ('Transferor Company') with the Company, under Section 233 of the Companies Act, 2013 read with Rule 25 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016.

   The Appointed Date under the Scheme is April 1, 2026. Since the Transferor Company is a wholly owned subsidiary of the Company, no shares of the Company will be issued, and no consideration will be payable pursuant to the Scheme. Consequently, there will be no change in the shareholding pattern or voting rights of the Company.

   Detailed disclosures regarding the Merger were previously submitted on February 3, 2026 are available at the Company's website at *Click Here* and remain accessible at BSE at *Click here* and NSE at *Click here*.

   The Scheme remains subject to statutory, regulatory, shareholder, and creditor approvals as required by law.

The Meeting of the Board of Directors of the Company commenced at 4.30 PM (IST) and concluded at 5.00 PM (IST).

We request you to take the above information on record.

Yours faithfully,
For Rubicon Research Limited
(Formerly known as Rubicon Research Private Limited)

DEEPASHREE OMKAR TANKSALE

Digitally signed by DEEPASHREE OMKAR TANKSALE
DN: c=IN, o=PERSONAL, title=9602, 2.5.4.20=a80b214753a3728a0e066d1b692aeb28c8fdde1958b7190c8f1512294e4c6614, postalCode=400603, st=Maharashtra, serialNumber=4ab53e9ad917b69cf200910723632675c1ef67f880d460105a99c9762ba5ee18, cn=DEEPASHREE OMKAR TANKSALE
Date: 2026.07.20 17:28:49 +05'30'

Deepashree Tanksale
Company Secretary
M. No. A28132